FRIDAY, April 24, 2026 (HealthDay News) — For patients with intracerebral hemorrhage, treatment with a once-daily regimen of three antihypertensive drugs is associated with a reduced rate of recurrent stroke, reports the April 23, 2026 issue of the journal. New England Journal of medicine.
Craig S. Anderson, MB, BS, Ph.D., from the George Institute for Global Health at the University of New South Wales in Sydney, and colleagues conducted a double-blind, randomized, placebo-controlled trial involving patients (mean age, 58 years) with a history of intracerebral hemorrhage whose blood pressure was less than 160 mmHg. based on After a two-week treatment phase, during which all patients received once a day a drug containing telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg (triple tablets), patients were randomly assigned to continue taking the triple tablets or the corresponding placebo (833 and respectively).
The researchers found that recurrent stroke occurred in 4.6 and 7.4 percent of patients in the triple and placebo groups, respectively, at a median follow-up of 2.5 years (hazard ratio, 0.61). During follow-up, the average systolic blood pressure was 127 and 138 mm Hg, respectively. There were fewer major cardiovascular events in the triple pill group compared with the placebo group (6.6 vs. 9.8 percent). Serious adverse events occurred in 23.2 and 26.0 percent of patients in the triple and placebo groups, respectively; premature termination of the trial regimen due to an adverse event was 13.6 and 6.0 percent, respectively.
“These study results have the potential to make real changes in how blood pressure is managed after stroke,” Anderson said in a statement. “This triple-pill combination helped patients reach their target blood pressure levels.”
Abstract / Full Text (subscription or payment may be required)
